✦ LIBER ✦

Pemetrexed in malignant pleural mesothelioma and the clinical outcome

✍ Scribed by Aija Knuuttila; Eija-Riitta Salomaa; Suvi Saikkonen; Saija Hurme; Jarmo Salo

Book ID: 114901911
Publisher: Wiley (Blackwell Publishing)
Year: 2011
Tongue: English
Weight: 179 KB
Volume: 6
Category: Article
ISSN: 1752-6981
DOI: 10.1111/j.1752-699x.2011.00252.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pemetrexed in advanced malignant pleural

Pemetrexed in advanced malignant pleural mesothelioma

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Pemetrexed/cisplatin worth it in maligna

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 139 KB

Vinorelbine in pemetrexed-pretreated pat

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

✍ Zucali, P.A.; Perrino, M.; Lorenzi, E.; Ceresoli, G.L.; De Vincenzo, F.; Simonel 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 553 KB

Significant response to carboplatin/peme

Significant response to carboplatin/pemetrexed chemotherapy in malignant pleural mesothelioma

✍ Fullam, L.; Carney, D.; McCaffrey, J. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Retreatment of recurrent malignant pleur

Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed

✍ Hidetoshi Hayashi; Isamu Okamoto; Yasuko Ichikawa; Masaki Miyazaki; Hiroshige Yo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 296 KB

Gemcitabine and vinorelbine in pemetrexe

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

✍ Paolo A. Zucali; Giovanni L. Ceresoli; Isabella Garassino; Fabio De Vincenzo; Ra 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## BACKGROUND Pemetrexed‐cisplatin chemotherapy is the standard of care in the first‐line treatment of unresectable malignant pleural mesothelioma (MPM). Second‐line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date.